# Stassets Investment

> Stassets Investment is a VC fund in Seoul backing Health Care, Medical and Biotechnology. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 11
- Last investment: Jun 2026
- Lead investor: 36%
- Last updated: Aug 2026
- Website: https://www.stassetsinv.com/

Stassets Investment is a VC fund in Seoul focused on Health Care and Medical. Stassets Investment focuses on the healthcare sector and specializes in early stage investments.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 45% |
| Medical | 4 | 36% |
| Biotechnology | 3 | 27% |
| Therapeutics | 2 | 18% |
| Pharmaceutical | 2 | 18% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 45% |
| Series B | 4 | 36% |
| Series C | 1 | 9% |
| Post-IPO Equity | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PROMEDIUS | Promedius is a MedTech startup, based in Seoul, Korea, focusing on optimizing radiologists workflow of medical imaging interpretation to drive improved patient outcomes. Our platform, AIdant, is providing an AI-enabled medical imaging cloud solution for individual doctors, medical institutions, and teleradiology centers. We believe ourcomprehensive zero-footprint AI solution can cover the geographic issues, after-hour issues, and lack of the radiologists issue in the diagnostic imaging market. | $14M | Series B | Jun 05, 2026 |  |
| Orum Therapeutics | Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M | Post-IPO Equity | Dec 18, 2025 |  |
| Nobo Medicine | Nobo Medicine is a clinical-stage biotech company focused on developing precision therapies for blood cancers and immune-related aging diseases. It uses biomarker-driven drug discovery and translational research to identify targeted treatments, aiming to improve outcomes in oncology and age-associated immune dysfunction through innovative,data-driven biomedical approaches. | $19.8M | Series C | Jul 28, 2025 |  |
| Avelos Therapeutics | Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. | $12.4M | Series B | May 02, 2024 |  |
| Algocare | Algocare is a AI based healthcare startup that offers specialised Nutrition as a Service (NaaS) to people and organisations. | $11.3M | Series A | Mar 14, 2024 |  |
| PROMEDIUS | Promedius is a MedTech startup, based in Seoul, Korea, focusing on optimizing radiologists workflow of medical imaging interpretation to drive improved patient outcomes. Our platform, AIdant, is providing an AI-enabled medical imaging cloud solution for individual doctors, medical institutions, and teleradiology centers. We believe ourcomprehensive zero-footprint AI solution can cover the geographic issues, after-hour issues, and lack of the radiologists issue in the diagnostic imaging market. | $8.5M | Series A | Mar 08, 2024 |  |
| Grade Health Chain | Grade Health Chain is a fintech company that develops insurance products which allows for premium discounts by collecting and analyzing health data. The platform developed by the company assesses the health grade based on the results of health checkups and provides an intuitive display of the user's health status. This allows users to receivevarious benefits based on their efforts to improve their health. | $4.5M | Series B | Mar 07, 2024 |  |
| Dencom | Dencom is an IT company that creates dental platforms for medical services. | $7.5M | Series A | Feb 22, 2024 |  |
| Vetching | Vetching started with the meaning of matching veterinarians and veterinary hospital customers by combining veterinarian and matching. | $6M | Series A | Aug 28, 2023 |  |
| C-Biomex | C-Biomex is a biotech drug development company that provides diagnostic therapy and radiopharmaceuticals. | $5M | Series B | Jun 22, 2022 |  |

10 of 11 investments shown.

## Co-investors
- [DSC Investment](https://shizune.co/investors/profile/dsc-investment) — VC Fund, 3 deals together
- [Woori Venture Partners](https://shizune.co/investors/profile/woori-venture-partners) — VC Fund, 3 deals together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 2 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 2 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 2 deals together
- [Quad Asset Management](https://shizune.co/investors/profile/quad-asset-management-2471) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Medical VC Funds in South Korea](https://shizune.co/investors/medical-vc-funds-south-korea)

## FAQ

### What does Stassets Investment invest in?

Stassets Investment invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Stassets Investment last invest?

The most recent investment recorded for Stassets Investment closed in Jun 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co